Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

All drugs

Safusidenib (AB-218, DS-1001)

Stage Phase 3

Sponsor Nuvation Bio

Route oral

Modality small molecule

Class mutant IDH1 inhibitor

Mechanism brain-penetrant mutant IDH1 inhibitor

Target IDH1 R132 (mutant)

Sources

company_release, as of 2026-11-07

https://investors.nuvationbio.com/news/news-details/2026/Nuvation-Bio-Announces-Positive-Updated-Phase-2-Data-and-Expansion-of-Safusidenib-Clinical-Program-with-Two-New-Studies-to-Explore-Broad-Spectrum-of-IDH1-Mutant-Glioma/default.aspx

Nuvation Bio release (2026, exact date not captured; page timed out on 11.07.2026, values from search record and the 10.27 brief): safusidenib J201 Phase 2 update, n = 27, 250 mg BID, confirmed ORR 51.9%, 36-month PFS 79.1%, median follow-up 38.8 months; new G209 and G307 studies (company release)

Brief source I8

publication, as of 2026-11-07

https://investors.nuvationbio.com/news/news-details/2026/Nuvation-Bio-Granted-FDA-Fast-Track-Designation-for-Safusidenib-for-Treatment-of-IDH1-Mutant-Glioma/default.aspx

Nuvation Bio release 08.20.2026: FDA Fast Track designation for safusidenib in IDH1-mutant glioma (search record)

Brief source I9

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT04458272

A Phase II Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-naive IDH1 Mutated WHO Grade II Glioma

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT05303519

A Phase 3, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT07712757

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Safusidenib in Participants With Grade 2 Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT07703436

A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT07832123

Safusidenib for Patients With Newly Diagnosed IDH1-mutant CNS WHO Grade 3 Oligodendroglioma and Astrocytoma - a Single Arm Phase II Study

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

J201 Phase 2

Registry NCT04458272

Phase Phase 2

Status Active, not recruiting

Enrollment 25

Start 2020-07-08

Primary completion 2023-03-10

Study completion 2027-02-28

Catalyst Primary completion. 03.10.2023. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Safusidenib 250 mg BID

Dose 250 mg

Regimen twice daily

Population IDH1-mutant grade 2 glioma, Japan (n = 27 per company; registry n = 25)

Estimand Single arm

confirmed objective response rate: 51.9%, median follow-up 38.8 months

36-month PFS rate: 79.1%, median follow-up 38.8 months

SIGMA

Registry NCT05303519

Phase Phase 3

Status Recruiting

Enrollment 365

Start 2023-06-05

Primary completion 2028-12-01

Study completion 2030-12-01

Catalyst Primary completion. 12.01.2028. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

G307

Registry NCT07712757

Phase Phase 3

Status Not yet recruiting

Enrollment 140

Start 2027-03

Primary completion 2029-05

Study completion 2032-03

Catalyst Primary completion. 05.2029. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

G209

Registry NCT07703436

Phase Phase 2

Status Recruiting

Enrollment 40

Start 2027-03

Primary completion 2030-09

Study completion 2032-03

Catalyst Primary completion. 09.2030. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

SAFU-G3

Registry NCT07832123

Phase Phase 2

Status Not yet recruiting

Enrollment 20

Start 2027-03

Primary completion 2029-03

Study completion 2029-09

Catalyst Primary completion. 03.2029. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Catalyst FDA Fast Track granted. 08.20.2026. Company release; event occurred.